04:58:20 (BST) 04:58:20 (BST)
CSE news on SQURPHARMA
2024-10-24: CB Free
SQURPHARMA: Please note that there will be no price limit today 24.10.2024 on the trading of the shares of the company following its corporate declaration.
2024-10-24: Recommendation of Dividend
SQURPHARMA: The Board of Directors has recommended 110% Cash Dividend for the year ended June 30, 2024. Date of AGM: 18.12.2024, Time: 10:00 AM, Venue: Virtual Platform. Record Date: 21.11.2024. The Company has also reported Consolidated EPS of Tk. 23.61, Consolidated NAV per share of Tk. 142.05 and Consolidated NOCFPS of Tk. 20.90 for the year ended June 30, 2024 as against Tk. 21.41, Tk. 129.95 and Tk. 9.64 respectively for the year ended June 30, 2023. The company has also informed that the Board of Directors of the company has approved Tk. 500 crore for BMRE, Capital Machineries and Land (for the purpose of future extension).
2024-10-16: Board Meeting
SQURPHARMA: The Company has informed that the Board Meeting will be held on October 23, 2024 at 3:00 PM to consider, among others, audited financial statements of the Company for the year ended June 30, 2024.
2024-05-06: Buy Confirmation
SQURPHARMA: Mr. Samuel S Chowdhury, one of the Directors of the Company, has further informed that he has completed his buying of 2,000,000 shares of the company at prevailing market price through Dhaka Stock Exchange PLC. as per declaration disseminated on 21.03.2024.
2024-04-30: Un-audited Financial Statement
SQURPHARMA: (Quarter 3) As per un-audited financial statements of the Company, Consolidated EPS was Tk. 5.55 for January-March 2024 as against Tk. 4.83 for January-March 2023; Consolidated EPS was Tk. 18.24 for July 2023-March 2024 as against Tk. 16.82 for July 2022-March 2023. Consolidated NOCFPS was Tk. 17.32 for July 2023-March 2024 as against Tk. 10.95 for July 2022-March 2023. Consolidated NAV per share was Tk. 137.39 as on March 31, 2024 and Tk. 129.95 as on June 30, 2023.
2024-04-24: Board Meeting
SQURPHARMA: The Company has informed that the Board Meeting of the Company will be held on April 29, 2024 at 03:00 PM to consider, among others, un-audited financial statements of the Company for the Third Quarter (Q3) period ended March 31, 2024.
2024-04-23: Buy Confirmation
SQURPHARMA: Mr. Tapan Chowdhury, one of the Directors of the Company, has further informed that he has completed his buying of 20,00,000 shares of the company at prevailing market price through Dhaka Stock Exchange PLC. as per declaration disseminated on 13.03.2024.
2024-03-21: Buy Intention
SQURPHARMA: Mr. Samuel S Chowdhury, one of the Directors of the Company, has reported his intention to buy 2,000,000 shares of the company at prevailing market price (in the Public and Block Market) through Dhaka Stock Exchange PLC. within April 30, 2024.
2024-03-13: Buy Intention
SQURPHARMA: Mr. Tapan Chowdhury, one of the Directors of the Company, has reported his intention to buy 20,00,000 shares of the company at prevailing market price (in the Public and Block Market) through Dhaka Stock Exchange PLC. within next 30 working days
2024-02-01: Cash Dividend Disbursement
SQURPHARMA: The Company has informed that it has disbursed the Cash Dividend for the year ended June 30, 2023 to the respective shareholders.
2024-02-01: Un-audited HY A/Cs
SQURPHARMA: (Quarter 2) As per un-audited half yearly accounts of the company, Consolidated EPS was Tk. 5.92 for October-December 2023 as against Tk. 5.78 for October-December 2022; Consolidated EPS was Tk. 12.69 for July-December 2023 as against Tk. 11.99 for July-December 2022. Consolidated NOCFPS was Tk. 14.37 for July-December 2023 as against Tk. 8.32 for July-December 2022. Consolidated NAV per share was Tk. 132.07 as on December 31, 2023 and Tk. 129.95 as on June 30, 2023.
2024-01-25: Board Meeting
SQURPHARMA: The Company has informed that the Board Meeting of the Company will be held on January 31, 2024 at 3:00 PM to consider, among others, un-audited financial statements of the Company for the Second Quarter (Q2) period ended December 31, 2023.
2024-01-11: Buy Confirmation
SQURPHARMA: Mrs. Ratna Patra, one of the Directors of the Company, has further informed that she has completed her buying of 1,000,000 shares of the company at prevailing market price through Dhaka Stock Exchange as per declaration disseminated on 05.12.2023.
2024-01-11: Buy Confirmation
SQURPHARMA: Mr. Tapan Chowdhury, one of the Directors of the Company, has further informed that he has completed his buying of 1,000,000 shares of the company at prevailing market price through Dhaka Stock Exchange as per declaration disseminated on 05.12.2023.
2024-01-11: Buy Confirmation
SQURPHARMA: Mr. Samuel S Chowdhury, one of the Directors of the Company, has further informed that he has completed his buying of 1,000,000 shares of the company at prevailing market price through Dhaka Stock Exchange as per declaration disseminated on 06.12.2023.
2023-12-14: Credit Rating
SQURPHARMA: Credit Rating Information and Services Limited (CRISL) has rated Square Pharmaceuticals Ltd. as ''AAA'' in the long term and ''ST-1'' in the short term along with a stable outlook in consideration of its audited financials up to June 30, 2023; also unaudited financials up to September 30, 2023 and other relevant quantitative as well as qualitative information up to the date of rating declaration.
2023-12-06: Buy Intention
SQURPHARMA: Mr. Samuel S Chowdhury, one of the Directors of the Company, has reported his intention to buy 1,000,000 shares of the company at prevailing market price (in the Public and Block Market) through Dhaka Stock Exchange Limited within next 30 working days.
2023-12-05: Buy Intention
SQURPHARMA: Mr. Tapan Chowdhury, one of the Directors of Square Pharmaceuticals PLC., has reported his intention to buy 1,000,000 shares of the company at prevailing market price (in the Public and Block Market) through Dhaka Stock Exchange Limited within next 30 working days.
2023-12-05: Buy Intention
SQURPHARMA: Mrs. Ratna Patra, one of the Directors of Square Pharmaceuticals PLC., has reported her intention to buy 1,000,000 shares of the company at prevailing market price (in the Public and Block Market) through Dhaka Stock Exchange Limited within next 30 working days.
2023-11-21: Cont-Regarding Equity Participation and Contract Manufacturing Agreement
SQURPHARMA: (cont) The Board of Directors further approved an agreement with M/S General Pharmaceuticals Ltd., Dhaka, Bangladesh, for contract manufacturing of products on behalf of the Company to meet the increased demand for an existing product. (end)
2023-11-21: Regarding Equity Participation and Contract Manufacturing Agreement
SQURPHARMA: Square Pharmaceuticals PLC. has informed that the Board of Directors in its meeting held on November 20, 2023 has approved an Equity participation of USD 1.00 million by the Company in ''Samson Pharma Inc., Philippines'', a Company to be engaged in the marketing and distribution of pharmaceutical products, incorporated in the Philippines, out of its initial investment of USD 2.5 million. The Board of Directors also approved the Debt-Equity ratio @ 60:40 and expected time to start the business of Samson Pharma Inc. by April 2024. (cont)
2023-11-15: Record Date tomorrow (16.11.2023)
SQURPHARMA: Trading of the shares of Square Pharmaceuticals PLC. will remain suspended on its record date i.e., 16.11.2023. Trading of the shares of the Company will resume on 19.11.2023.
2023-11-15: Un-audited Financial Statements
SQURPHARMA: (Quarter 1) As per un-audited financial statements of the Company, Consolidated EPS was Tk. 6.77 for July-September 2023 as against Tk. 6.20 for July-September 2022; Consolidated NOCFPS was Tk. 9.54 for July-September 2023 as against Tk. 5.87 for July-September 2022. Consolidated NAV per share was Tk. 136.79 as on September 30, 2023 and Tk. 129.95 as on June 30, 2023.
2023-11-13: Spot trade from tomorrow (14.11.2023)
SQURPHARMA: Trading of the shares of Square Pharmaceuticals PLC. will be allowed only in the Spot Market from 14.11.2023 to 15.11.2023 as the record date of the Company is on 16.11.2023.
2023-11-09: Board Meeting
SQURPHARMA: Square Pharmaceuticals PLC. has informed that the Board Meeting of the Company will be held on November 14, 2023 at 3:00 PM to consider, among others, un-audited financial statements of the Company for the First Quarter (Q1) period ended September 30, 2023.
2023-10-23: CB Free
SQURPHARMA: Please note that there will be no price limit today 23.10.2023 on the trading of the shares of the company following its corporate declaration. However, the floor price shall be applicable accordingly.
2023-10-23: Recommendation of Dividend and BMRE, Capital Machineries & Land
SQURPHARMA: The Board of Directors has recommended 105% cash dividend for the year ended June 30, 2023. The Board has also approved Tk. 400.00 crore for BMRE, Capital Machineries and Lands for future expansion. Date of AGM: 14.12.2023, Time: 10:00 AM, Venue: Digital Platform. Record Date: 16.11.2023. The Company has also reported Consolidated EPS of Tk. 21.41, Consolidated NAV per share of Tk. 129.95 and Consolidated NOCFPS of Tk. 9.64 for the year ended June 30, 2023 as against Tk. 20.48, Tk. 118.68 and Tk. 14.52 respectively for the year ended June 30, 2022.
2023-10-18: Reschedule of Board Meeting Time
SQURPHARMA: Square Pharmaceuticals PLC. has informed that the Board Meeting of the Company will be held on October 22, 2023 at 5:00 PM instead of 3:00 PM to consider, among others, audited financial statements of the Company for the year ended June 30, 2023.
2023-10-12: Board Meeting
SQURPHARMA: Square Pharmaceuticals PLC. has informed that the Board Meeting of the Company will be held on October 22, 2023 at 3:00 PM to consider, among others, audited financial statements of the Company for the year ended June 30, 2023.
2023-08-08: Regarding Contract Manufacturing Agreement with M/s Euro Pharma Ltd.
SQURPHARMA: Square Pharmaceuticals PLC. has informed that the Board of Directors in its meeting held on August 07, 2023 has approved an agreement with M/s Euro Pharma Ltd. for contract manufacturing of some products on behalf of the Company to meet increased demand of existing products and to introduce new products.
2023-08-03: Regarding Contract Manufacturing Agreement with M/s Aristopharma Ltd.
SQURPHARMA: Square Pharmaceuticals PLC. has informed that the Board of Directors in its meeting held on July 12, 2023 has approved an agreement with M/s Aristopharma Ltd. for contract manufacturing of some products on behalf of the company to meet increased demand of existing products and to introduce new products.
2023-07-13: Contract manufacturing Agreement
SQURPHARMA: Square Pharmaceuticals PLC. has informed that the Board of Directors of the Company has approved agreements with M/s Aristopharma Ltd., Dhaka, Bangladesh for contract manufacturing of some products on behalf of Square Pharmaceuticals PLC. to meet increased demand of existing products and to introduce new products.
2023-06-21: Name Change of the Company
SQURPHARMA: Chittagong Stock Exchange PLC (CSE) has approved the proposed name change of the Company. Accordingly, the name of the Company will be 'Square Pharmaceuticals PLC.' instead of 'Square Pharmaceuticals Limited' with effect from June 22, 2023. Other things (except name) will remain unchanged.
2023-05-02: cont-Un-audited Financial Statement
SQURPHARMA: (Quarter 3)(Cont) The Company has also informed that NOCFPS has been decreased due to amidst the ongoing complexity in the procurement of raw materials and protracted lead time, the Group has paid its regular suppliers in advance to ensure supply chain does not face any disruption.(end)
2023-05-02: Un-audited Financial Statement
SQURPHARMA: (Quarter 3) As per un-audited financial statements of Square Pharmaceuticals Ltd., Consolidated EPS was Tk. 4.83 for January-March 2023 as against Tk. 5.15 for January-March 2022; Consolidated EPS was Tk. 16.82 for July 2022-March 2023 as against Tk. 16.03 for July 2021-March 2022. Consolidated NOCFPS was Tk. 10.95 for July 2022-March 2023 as against Tk. 13.87 for July 2021-March 2022. Consolidated NAV per share was Tk. 123.33 as on March 31, 2023 and Tk. 116.70 as on June 30, 2022. (Cont)
2023-04-25: Board Meeting
SQURPHARMA: Square Pharmaceuticals Ltd. has informed that the Board Meeting of the Company will be held on April 30, 2023 at 3:00 PM to consider, among others, un-audited financial statements of the Company for the Third Quarter (Q3) period ended March 31, 2023.
2023-02-02: Cash Dividend Disbursement
SQURPHARMA: Square Pharmaceuticals Ltd. has informed that it has disbursed the cash dividend for the year ended June 30, 2022 to the respective shareholders.
2023-01-31: Un-audited HY A/Cs
SQURPHARMA: As per un-audited HY A/Cs of Square Pharmaceuticals Ltd., Consolidated EPS was Tk. 5.78 for October-December 2022 as against Tk. 5.24 for October-December 2021; Consolidated EPS was Tk. 11.99 for July-December 2022 as against Tk. 10.88 for July-December 2021. Consolidated NOCFPS was Tk. 8.32 for July-December 2022 as against Tk. 10.89 for July-December 2021. Consolidated NAV per share was Tk. 118.53 as on December 31, 2022 and Tk. 116.70 as on June 30, 2022.
2023-01-24: Board Meeting
SQURPHARMA: Square Pharmaceuticals Ltd. has informed that the Board Meeting of the Company will be held on January 30, 2023 at 3:00 PM to consider, among others, un-audited financial statements of the Company for the Second Quarter (Q2) period ended December 31, 2022.
2022-12-14: Credit Rating
SQURPHARMA: Credit Rating Information and Services Limited (CRISL) has rated Square Pharmaceuticals Ltd. as ''AAA'' in the long term and ''ST-1'' in the short term along with a stable outlook in consideration of its audited financials up to June 30, 2022; also unaudited financials up to September 30, 2022 and other relevant quantitative as well as qualitative information up to the date of rating declaration.
2022-11-27: Record Date tomorrow (28.11.2022)
SQURPHARMA: Trading of the shares of Square Pharmaceuticals Ltd. will remain suspended on its record date i.e., 28.11.2022. Trading of the shares of the Company will resume on 29.11.2022.
2022-11-23: Spot trade from tomorrow (24.11.2022)
SQURPHARMA: Trading of the shares of Square Pharmaceuticals Ltd. will be allowed only in the Spot Market from 24.11.2022 to 27.11.2022 as the record date of the Company is on 28.11.2022.
2022-11-15: Un-audited Financial Statements
SQURPHARMA: (Quarter 1) As per un-audited financial statements of Square Pharmaceuticals Ltd., Consolidated EPS was Tk. 6.20 for July-September 2022 as against Tk. 5.64 for July-September 2021; Consolidated NOCFPS was Tk. 5.87 for July-September 2022 as against Tk. 6.61 for July-September 2021. Consolidated NAV per share was Tk. 122.84 as on September 30, 2022 and Tk. 116.70 as on June 30, 2022.
2022-11-09: Board Meeting
SQURPHARMA: Square Pharmaceuticals Ltd. has informed that the Board Meeting of the Company will be held on November 14, 2022 at 3:00 PM to consider, among others, un-audited financial statements of the company for the First Quarter (Q1) period ended September 30, 2022.
2022-10-23: CB free
SQURPHARMA: Please note that there will be no price limit today 23.10.2022 on the trading of the shares of the company following its corporate declaration, however, as per the BSEC Order No. BSEC/CMRRCD/2001-07/39 dated July 28, 2022, the floor price shall be applicable accordingly.
2022-10-23: Recommendation of Dividend and BMRE, Capital Machineries & Land purchase
SQURPHARMA: The Board of Directors has recommended 100% cash dividend for the year ended June 30, 2022. The Board has also approved Tk. 300.00 crore for BMRE, Capital Machineries and Lands for future expansion. Date of AGM: 24.12.2022, Time: 10:00 AM, Venue: Digital Platform. Record Date: 28.11.2022. The Company has also reported Consolidated EPS of Tk. 20.51, Consolidated NAV per share of Tk. 116.70 and Consolidated NOCFPS of Tk. 14.52 for the year ended June 30, 2022 as against Tk. 17.99, Tk. 102.54 and Tk. 12.38 respectively for the same period of the previous year.
2022-10-11: Board Meeting
SQURPHARMA: Square Pharmaceuticals Ltd. has informed that the Board Meeting of the Company will be held on October 20, 2022 at 3:00 PM to consider, among others, audited financial statements of the Company for the year ended June 30, 2022.
2022-05-26: Cont-Regarding the Fire at the factory premises
SQURPHARMA(cont): It will cause the hampering of production of 50 (fifty) products by the company and reduce the revenue and profit by about Tk. 50.00 crore and Tk. 8.00 crore respectively. The ascertainment of damage in the fire is under active security by the tripartite team comprised of the experts of the company, firefighting units, and surveyors of insurance companies. However, the LVP plants is fully insured under the coverage of the Industrial All Risk Insurance Policy, and restoring the damaged facility and production may take 2/3 years.(end)
2022-05-26: Regarding the Fire at the factory premises
SQURPHARMA: Square Pharmaceuticals Ltd. has informed that a fire broke out in the Large Volume Parenteral (LVP) Plant at the factory promises at Kaliakoir, Gazipur of the Company on May 23, 2022 at about 12.00 noon and was brought under control at about 11.00 p.m. by the hardworking of the 14 units of firefighting units, which was immediately broadcast and published by various broadcast and print media.(cont)
2022-05-05: Buy Confirmation
SQURPHARMA: Mr. Samuel S Chowdhury, one of the Directors of Square Pharmaceuticals Ltd., has further informed that he has completed his buying of 2,25,000 shares of the company at prevailing market price through Dhaka Stock Exchange as per declaration disseminated on 10.04.2022.
2022-05-05: Buy Confirmation
SQURPHARMA: Mr. Tapan Chowdhury, one of the Directors of Square Pharmaceuticals Ltd., has further informed that he has completed his buying of 2,25,000 shares of the company at prevailing market price through Dhaka Stock Exchange as per declaration disseminated on 10.04.2022.
2022-05-05: Buy Confirmation
SQURPHARMA: Mr. Anjan Chowdhury, one of the Directors of Square Pharmaceuticals Ltd., has further informed that he has completed his buying of 2,25,000 shares of the company at prevailing market price through Dhaka Stock Exchange as per declaration disseminated on 10.04.2022.
2022-05-05: Buy Confirmation
SQURPHARMA: Mrs. Ratna Patra, one of the Directors of Square Pharmaceuticals Ltd., has further informed that she has completed her buying of 2,25,000 shares of the company at prevailing market price through Dhaka Stock Exchange as per declaration disseminated on 10.04.2022.
2022-04-28: Cont-Un-audited Financial Statements
SQURPHARMA(cont):Reason for Significant deviation in Consolidated EPS and Consolidated NOCFPS: Consolidated EPS increased in sales revenue along with proficient usage of materials led to increased gross profit for the reporting period. Favorable movement in foreign exchange transactions has also added in increased net operating profit. The reduced corporate tax rate for the period resulted in the increment of EPS. Consolidated NOCFPS increased the growth in their business volume and efficient utilization of working capital along with reduction in tax expense.(end)
2022-04-28: Un-audited Financial Statements
SQURPHARMA: (Quarter 3) As per un-audited financial statements of Square Pharmaceuticals Ltd., Consolidated EPS was Tk. 5.15 for January-March 2022 as against Tk. 4.36 for January-March 2021; Consolidated EPS was Tk. 16.03 for July 2021-March 2022 as against Tk. 13.12 for July 2020-March 2021. Consolidated NOCFPS was Tk. 13.87 for July 2021-March 2022 as against Tk. 9.40 for July 2020-March 2021. Consolidated NAV per share was Tk. 112.39 as on March 31, 2022 and Tk. 102.54 as on June 30, 2021.(cont)
2022-04-21: Board Meeting
SQURPHARMA: Square Pharmaceuticals Ltd. has informed that the Board Meeting of the Company will be held on April 27, 2022 at 2:15 PM to consider, among others, un-audited financial statements of the Company for the Third Quarter (Q3) period ended March 31, 2022.
2022-04-10: Buy Intention
SQURPHARMA: Mr. Samuel S Chowdhury, one of the Directors of Square Pharmaceuticals Ltd., has reported his intention to buy 2,25,000 shares of the Company at prevailing market price (in the Public Market) through Dhaka Stock Exchange within April 28, 2022.
2022-04-10: Buy Intention
SQURPHARMA: Mr. Tapan Chowdhury, one of the Directors of Square Pharmaceuticals Ltd., has reported his intention to buy 2,25,000 shares of the Company at prevailing market price (in the Public Market) through Dhaka Stock Exchange within April 28, 2022.
2022-04-10: Buy Intention
SQURPHARMA: Mr. Anjan Chowdhury, one of the Directors of Square Pharmaceuticals Ltd., has reported his intention to buy 2,25,000 shares of the Company at prevailing market price (in the Public Market) through Dhaka Stock Exchange within April 28, 2022.
2022-04-10: Buy Intention
SQURPHARMA: Mrs. Ratna Patra, one of the Directors of Square Pharmaceuticals Ltd., has reported her intention to buy 2,25,000 shares of the Company at prevailing market price (in the Public Market) through Dhaka Stock Exchange within April 28, 2022.
2022-02-01: Cont-Un-audited HY A/C
SQURPHARMA: (Quarter 2) (Cont) The company informed that increase in sales revenue along with proficient usage of materials let to increased gross profit for the reporting period. Favorable movement in foreign exchange transactions has also aided in increased net operating profit. The reduced corporate tax rate for the period resulted in the increment consolidated EPS. The growth in business volume and efficient utilization of working capital along with reduction in tax expense resulted in increased consolidated NOCFPS.(end)
2022-02-01: Un-audited HY A/C
SQURPHARMA: (Quarter 2) As per un-audited half yearly accounts of Square Pharmaceuticals Ltd., Consolidated EPS was Tk. 5.24 for October-December 2021 as against Tk. 4.33 for October-December 2020; Consolidated EPS was Tk. 10.88 for July-December 2021 as against Tk. 8.76 for July-December 2020. Consolidated NOCFPS was Tk. 10.89 for July-December 2021 as against Tk. 7.28 for July-December 2020. Consolidated NAV per share was Tk. 107.36 as on December 31, 2021 and Tk. 102.54 as on June 30, 2021.(Cont)
2022-01-25: Board Meeting
SQURPHARMA: Square Pharmaceuticals Ltd. has informed that the Board Meeting of the Company will be held on January 31, 2022 at 3:00 PM to consider, among others, un-audited financial statements of the Company for the Second Quarter (Q2) period ended December 31, 2021.
2022-01-20: Cash Dividend Disbursement
SQURPHARMA: Square Pharmaceuticals Ltd. has informed that it has disbursed the cash dividend for the year ended June 30, 2021 to the respective shareholders.
2021-12-19: Credit Rating
SQURPHARMA: Credit Rating Information and Services Limited (CRISL) has rated Square Pharmaceuticals Ltd. as ''AAA'' in the long term and ''ST-1'' in the short term along with a stable outlook in consideration of its audited financials up to June 30, 2021; also unaudited financials up to September 30, 2021 and other relevant quantitative as well as qualitative information up to the date of rating declaration.
2021-11-21: Record Date tomorrow (22.11.2021)
SQURPHARMA: Trading of the shares of Square Pharmaceuticals Ltd. will remain suspended on its record date i.e., 22.11.2021. Trading of the shares of the Company will resume on 23.11.2021.
2021-11-17: Spot trade from tomorrow (18.11.2021)
SQURPHARMA: Trading of the shares of Square Pharmaceuticals Ltd. will be allowed only in the Spot Market from 18.11.2021 to 21.11.2021 as the record date of the Company is on 22.11.2021.
2021-11-15: Un-audited Financial Statements
SQURPHARMA: (Quarter 1) As per un-audited financial statements of Square Pharmaceuticals Ltd., Consolidated EPS was Tk. 5.64 for July-September 2021 as against Tk. 4.44 for July-September 2020; Consolidated NOCFPS was Tk. 6.61 for July-September 2021 as against Tk. 3.30 for July-September 2020. Consolidated NAV per share was Tk. 108.71 as on September 30, 2021 and Tk. 102.54 as on June 30, 2021. The Company has informed that growth in business volume and efficient utilization of working capital along with reduction in tax expense resulted in increased Consolidated Net Operating Cash Flow Per Share.
2021-11-08: Board Meeting
SQURPHARMA: Square Pharmaceuticals Ltd. has informed that the Board Meeting of the Company will be held on November 14, 2021 at 3:00 PM to consider, among others, un-audited financial statements of the Company for the First Quarter (Q1) period ended on September 30, 2021.
2021-10-25: Cont-Recommendation of Dividend (Additional Information)
SQURPHARMA: (Cont) We have been able to earn a significant amount of other income in form of dividend, gain on bonds and marketable securities, interest etc. (please see note 21 of standalone annual report) which allowed us to obtain a healthy 7.63% increment in other income compared to last year's negative growth of 3.80%. Furthermore, the reduced corporate tax rate (22.5% from last year's 25%) for publicly listed entities for the concerned financial year (2020-21) helped us reducing tax expenses which in turn resulted in the increment of EPS. ''(end)
2021-10-25: Recommendation of Dividend (Additional Information)
SQURPHARMA: Square Pharmaceuticals Ltd. has further informed that the Clarification on increase in EPS are as follows: ''The growth in our core business i.e. sales of pharmaceutical products has positively affected the EPS for the current year. Moreover, proficient usage of raw materials and optimized utilization of manufacturing overhead while maintaining stringent health and safety measurements to prevent Covid-19 has helped us maintaining a good Cost of Goods Sold for the year. The overall impact was a good 11% growth in gross profit which has contributed towards earning a good EPS. Additionally, our prudent investment decision has paid off quite well. (Cont)
2021-10-24: CB free
SQURPHARMA: Please note that there will be no price limit today 24.10.2021 on the trading of the shares of the Company following its corporate declaration.
2021-10-24: Recommendation of Dividend and BMRE, Capital Machineries & Land purchase
SQURPHARMA: The Board of Directors has recommended 60% cash dividend for the year ended on June 30, 2021. The Board has also approved Tk. 300.00 crore for BMRE, Capital Machineries and Lands for future expansion. Date of AGM: 15.12.2021, Time: 10:00 AM, Venue: Digital Platform. Record Date: 22.11.2021. The Company has also reported Consolidated EPS of Tk. 17.99, Consolidated NAV per share of Tk. 102.54 and Consolidated NOCFPS of Tk. 12.43 for the year ended on June 30, 2021 as against Tk. 15.07, Tk. 87.28 and Tk. 12.14 respectively for the same period of the previous year.
2021-10-10: Board Meeting
SQURPHARMA: Square Pharmaceuticals Ltd. has informed that the Board Meeting of the Company will be held on October 21, 2021 at 3:00 PM to consider, among others, audited financial statements of the Company for the year ended on June 30, 2021.
2021-05-12: Response to DSE's Query
SQURPHARMA: In response to a DSE query dated May 09, 2021 regarding clarification on recent news published in the newspaper on launching factory in Kenya, Square Pharmaceuticals Ltd. has informed that "It is a 100% subsidiary of Square Pharmaceuticals Limited, Bangladesh and the construction of the pharmaceuticals manufacturing facility in Nairobi, Kenya is at finishing stage. It shall go for commercial production subject to completion of Kenyan regulatory compliance process by August 2021."
2021-05-09: Cont-Un-audited Financial Statements
SQURPHARMA: (Quarter 3) (cont) Consolidated EPS increased due to positive revenue. Consolidated NOCFPS decreased due to higher investment on working capital and higher advance tax payment to facilitate revenue growth in comparing to the same reporting period of previous fiscal year.(end)
2021-05-09: Un-audited Financial Statements
SQURPHARMA: (Quarter 3) As per un-audited financial statements of Square Pharmaceuticals Ltd., Consolidated EPS was Tk. 4.36 for January-March 2021 as against Tk. 4.08 for January-March 2020; Consolidated EPS was Tk. 13.12 for July 2020-March 2021 as against Tk. 11.85 for July 2019-March 2020. Consolidated NOCFPS was Tk. 9.40 for July 2020-March 2021 as against Tk. 9.64 for July 2019-March 2020. Consolidated NAV per share was Tk. 96.43 as on March 31, 2021 and Tk. 87.28 as on June 30, 2020. Reason for Significant deviation in Consolidated NAV per share, Consolidated EPS and Consolidated NOCFPS: Consolidated NAV per share is increased due to incremental Net Profit in comparing to the reporting period ended on March 31, 2020. (cont)
2021-05-02: Board Meeting
SQURPHARMA: Square Pharmaceuticals Ltd. has informed that the Board Meeting of the Company will be held on May 06, 2021 at 1:00 PM to consider, among others, un-audited financial statements of the Company for the Third Quarter (Q3) period ended on March 31, 2021.
2021-01-31: Un-audited HY A/Cs
SQURPHARMA: (Quarter 2) As per un-audited half yearly accounts of Square Pharmaceuticals Ltd., Consolidated EPS was Tk. 4.33 for October-December 2020 as against Tk. 3.98 for October-December 2019; Consolidated EPS was Tk. 8.76 for July-December 2020 as against Tk. 7.77 for July-December 2019. Consolidated NOCFPS was Tk. 7.28 for July-December 2020 as against Tk. 5.60 for July-December 2019. Consolidated NAV per share was Tk. 92.47 as on December 31, 2020 and Tk. 87.28 as on June 30, 2020.
2021-01-24: Cash Dividend Disbursement
SQURPHARMA: Square Pharmaceuticals Ltd. has informed that it has disbursed the cash dividend for the year ended on June 30, 2020 to the respective shareholders.
2021-01-24: Board Meeting
SQURPHARMA: Square Pharmaceuticals Ltd. has informed that the Board Meeting of the Company will be held on January 28, 2021 at 3:00 PM to consider, among others, un-audited financial statements of the Company for the Second Quarter (Q2) period ended on December 31, 2020.
2020-12-24: Credit Rating
SQURPHARMA: Credit Rating Information and Services Limited (CRISL) has rated Square Pharmaceuticals Ltd. as "AAA" in the long term and "ST-1" in the short term along with a stable outlook in consideration of its audited financials up to June 30, 2020; unaudited financials up to September 30, 2020 and other relevant quantitative as well as qualitative information up to the date of rating declaration.
2020-12-23: Bonus Shares Credited
SQURPHARMA: Square Pharmaceuticals Ltd. has informed that it has credited the Bonus shares for the year ended on June 30, 2020 have already been credited through CDBL to the respective shareholders' BO Accounts on December 23, 2020.
2020-11-22: Cont-Auditor's Opinion
SQURPHARMA(cont): Note 8- SHORT TERM LOAN (Unsecured): Balance of Short Term Loan (Unsecured) as at 30 June 2020 was BDT 4,885,090,120 and as at 30 June 2019 was BDT 2,937,071,066. This loan consists of loan given to Square Textiles Ltd, Square Fashions Ltd., Square Hospitals Ltd., Square Lifesciences Ltd."(end)
2020-11-22: Auditor's Opinion
SQURPHARMA: The auditor of Square Pharmaceuticals Ltd has given the following "Emphasis of Matter" in the audit report of the Company for the year ended on 30 June 2020. "Emphasis of Matter: We draw attention to the note no. 8 to the separate financial statements, which describes the loans given to subsidiaries and associates as well as companies with common directors. The company obtained approval for such loans from the Board of Directors. Our opinion is not modified in this regard.(cont)
2020-11-19: Record Date on 22.11.2020
SQURPHARMA: Trading of the shares of Square Pharmaceuticals Ltd. will remain suspended on its record date i.e., 22.11.2020. Trading of the shares of the Company will resume on 23.11.2020.
2020-11-17: Spot trade from tomorrow (18.11.2020)
SQURPHARMA: Trading of the shares of Square Pharmaceuticals Ltd. will be allowed only in the Spot Market from 18.11.2020 to 19.11.2020 as the record date of the Company is on 22.11.2020.
2020-11-15: Un-audited Financial Statements
SQURPHARMA: (Quarter 1) As per un-audited financial statements of Square Pharmaceuticals Ltd., Consolidated EPS was Tk. 4.66 for July-September 2020 as against Tk. 3.97 for July-September 2019; Consolidated NOCFPS was Tk. 3.47 for July-September 2020 as against Tk. 3.87 for July-September 2019. Consolidated NAV per share was Tk. 97.13 as on September 30, 2020 and Tk. 91.57 as on June 30, 2020.
2020-11-09: Board Meeting
SQURPHARMA: Square Pharmaceuticals Ltd. has informed that the Board Meeting of the Company will be held on November 12, 2020 at 3:00 PM to consider, among others, un-audited financial statements of the Company for the First Quarter (Q1) period ended on September 30, 2020.
2020-10-25: CB free
SQURPHARMA: Please note that there will be no price limit today 25.10.2020 on the trading of the shares of the Company following its corporate declaration, however, as per the BSEC Order No. BSEC/CMRRCD/2001-07/04 dated March 19, 2020, the floor price shall be applicable accordingly.
2020-10-25: Cont-Recommendation of Dividend and BMRE, Capital Machineries & Land purchase
SQURPHARMA:(Cont) The Company also informed that i) Bonus shares has been recommended in view to utilize its retained amount as capital for business expansion. ii) Bonus share is declared out of accumulated profit. iii) Bonus share is not declared from capital reserve or revaluation reserve or any unrealized gain or out of profit earned prior to incorporation of the Company or through reducing paid up capital or through doing anything so that the post dividend retained earnings become negative or a debit balance.(end)
2020-10-25: Recommendation of Dividend and BMRE, Capital Machineries & Land purchase
SQURPHARMA: The Board of Directors has recommended 47% cash and 5% stock dividend for the year ended on June 30, 2020. The Board has also approved Tk. 250.00 crore for BMRE, Capital Machineries and Lands for future expansion. Date of AGM: 15.12.2020, Time: 10:00 AM, Venue: Digital Platform. Record Date: 22.11.2020. The Company has also reported Consolidated EPS of Tk. 15.82, Consolidated NAV per share of Tk. 91.57 and Consolidated NOCFPS of Tk. 12.75 for the year ended on June 30, 2020 as against Tk. 14.98, Tk. 80.40 and Tk. 14.68 respectively for the same period of the previous year.(Cont)
2020-10-13: Board Meeting
SQURPHARMA: Square Pharmaceuticals Ltd. has informed that the Board Meeting of the Company will be held on October 22, 2020 at 3:00 PM to consider, among others, audited financial statements of the Company for the year ended on June 30, 2020.
2020-06-09: Un-audited Financial Statements
SQURPHARMA: (Quarter 3) As per un-audited financial statements of Square Pharmaceuticals Ltd., Consolidated EPS was Tk. 4.28 for January-March 2020 as against Tk. 3.69 for January-March 2019; Consolidated EPS was Tk. 12.44 for July 2019-March 2020 as against Tk. 11.15 for July 2018-March 2019. Consolidated NOCFPS was Tk. 10.13 for July 2019-March 2020 as against Tk. 10.57 for July 2018-March 2019. Consolidated NAV per share was Tk. 88.19 as on March 31, 2020 and Tk. 80.40 as on June 30, 2019.
2020-06-01: Board Meeting
SQURPHARMA: Square Pharmaceuticals Ltd. has informed that the Board Meeting of the Company will be held on June 08, 2020 at 3:00 PM to consider, among others, un-audited financial statements of the Company for the Third Quarter (Q3) period ended on March 31, 2020.
2020-03-24: Contract manufacturing agreement
SQURPHARMA: Square Pharmaceuticals Ltd. has informed that the Board of Directors of the Company has approved agreements with M/s Renata Oncology Ltd. and M/s Apex Pharma Ltd., Dhaka, Bangladesh for contract manufacturing of some products on behalf of the Company to meet increased demand of existing products and to introduce new products.
2020-02-26: Buy Confirmation
SQURPHARMA: Mrs. Ratna Patra, one of the Directors of Square Pharmaceuticals Ltd., has further reported that she has completed her buy of 3,00,000 shares of the Company at prevailing market price through Stock Exchange as per declaration disseminated on 21.01.2020.
2020-02-26: Buy Confirmation
SQURPHARMA: Mr. Anjan Chowdhury, one of the Directors of Square Pharmaceuticals Ltd., has further reported that he has completed his buy of 3,00,000 shares of the Company at prevailing market price through Stock Exchange as per declaration disseminated on 21.01.2020.
2020-02-20: Buy Confirmation
SQURPHARMA: Mr. Samuel S Chowdhury, one of the Directors of Square Pharmaceuticals Ltd., has further reported that he has completed his buy of 3,00,000 shares of the Company at prevailing market price through Stock Exchange as per declaration disseminated on 16.01.2020.
2020-02-20: Buy Confirmation
SQURPHARMA: Mr. Tapan Chowdhury, one of the Directors of Square Pharmaceuticals Ltd., has further reported that he has completed his buy of 3,00,000 shares of the Company at prevailing market price through Stock Exchange as per declaration disseminated on 16.01.2020.
2020-02-18: Decision to establish a virtually wholly owned subsidiary Company
SQURPHARMA: Square Pharmaceuticals Ltd. has informed that the Board of Directors has taken the following decisions i) The Company shall establish a virtually wholly owned subsidiary Company in the name and style of ''Square Lifesciences Ltd.'' in order to manufacture pharmaceuticals Oral Solid Dosage products. ii) Initial estimated total project cost will be Tk. 350.00 crore and to be financed by internally generated funds by the Square Pharmaceuticals Ltd. /Sponsors of Square Lifesciences Ltd. and iii) It is expected that the project would be completed by June, 2023.
2020-01-30: Un-audited HY A/Cs
SQURPHARMA: (Quarter 2) As per un-audited half yearly accounts of Square Pharmaceuticals Ltd., Consolidated EPS was Tk. 4.18 for October-December 2019 as against Tk. 3.70 for October-December 2018; Consolidated EPS was Tk. 8.16 for July-December 2019 as against Tk. 7.46 for July-December 2018. Consolidated NOCFPS was Tk. 5.88 for July-December 2019 as against Tk. 6.83 for July-December 2018. Consolidated NAV per share was Tk. 84.12 as on December 31, 2019 and Tk. 80.40 as on June 30, 2019.
2020-01-23: Board Meeting
SQURPHARMA: Square Pharmaceuticals Ltd. has informed that the Board Meeting of the Company will be held on January 29, 2020 at 3:00 PM to consider, among others, un-audited financial statements of the Company for the Second Quarter (Q2) period ended on December 31, 2019.
2020-01-21: Buy Intention
SQURPHARMA: Mr. Anjan Chowdhury, one of the Directors of Square Pharmaceuticals Ltd., has reported his intention to buy 3,00,000 shares of the Company at prevailing market price (in the Public Market) through Stock Exchanges (DSE & CSE) within next 30 working days.
2020-01-21: Buy Intention
SQURPHARMA: Mrs. Ratna Patra, one of the Directors of Square Pharmaceuticals Ltd., has reported her intention to buy 3,00,000 shares of the Company at prevailing market price (in the Public Market) through Stock Exchanges (DSE & CSE) within next 30 working days.
2020-01-21: Dividend Disbursement
SQURPHARMA: Square Pharmaceuticals Ltd. has informed that the Bonus Shares of the Company for the year ended on June 30, 2019 have already been credited to the respective shareholders' BO Accounts and the cash dividend for the year ended on June 30, 2019 has also been disbursed.
2020-01-16: Buy Intention
SQURPHARMA: Mr. Samuel S Chowdhury, one of the Directors of Square Pharmaceuticals Ltd., has reported his intention to buy 3,00,000 shares of the Company at prevailing market price (in the Public Market) through Stock Exchanges (DSE & CSE) within next 30 working days.
2020-01-16: Buy Intention
SQURPHARMA: Mr. Tapan Chowdhury, one of the Directors of Square Pharmaceuticals Ltd., has reported his intention to buy 3,00,000 shares of the Company at prevailing market price (in the Public Market) through Stock Exchanges (DSE & CSE) within next 30 working days.
2019-12-23: Credit Rating
SQURPHARMA: Credit Rating Information and Services Limited (CRISL) has informed that the Rating Committee of CRISL has assigned the rating to Square Pharmaceuticals Ltd. as ''AAA'' in the long term and ''ST-1'' in the short term along with a stable outlook in consideration of its audited financials up to June 30, 2019; unaudited financials up to September 30, 2019 and other relevant quantitative as well as qualitative information up to the date of rating declaration.
2019-12-18: Bonus Shares Credited
SQURPHARMA: Square Pharmaceuticals Ltd. has informed that the Bonus Shares of the Company for the year ended on June 30, 2019 have already been credited through CDBL to the respective shareholders' BO Accounts December 17, 2019.
2019-12-15: Cont4-Auditor's Opinion
SQURPHARMA(cont4):Compensation of shareholders of Square Herbal & Nutraceuticals Ltd. is based on cash at a book value shares as on 30 June, 2017 subject to approval by the Court of Jurisdiction, Hon'ble High Court Division of the Supreme Court of Bangladesh. IFRS Followed for the Business Combination: The Company accounts for business combinations using the acquisition method when control is transferred to the Company. The consideration transferred in the acquisition is generally measured at fair value,as are the identifiable net assets acquired. As the consideration transferred in the acquisition date is equals to net assets acquired at acquisition date, there is no goodwill or gain on bargain purchase arises as per para-9 of lFRS 3.(end)
2019-12-15: Cont3-Auditor's Opinion
SQURPHARMA(cont):After approval of Board of Directors and consent of shareholders, the Hon'ble High Court Division of the Supreme Court of Bangladesh has sanctioned the scheme of amalgamation of Square Herbal & Nutraceuticals with Square Pharmaceuticals Ltd. on 29th October, 2018. The merger has been executed with effect from January 01, 2019. Purchase Consideration: Square Pharmaceuticals Ltd. holds 99.50% of the Paid-up Capital of Square Formulations Ltd. with only 0.50% being held by the minority shareholders. Compensation of the minority shareholders is based on cash at a book value shares as on 30 June, 2017 subject to approval by the Court of Jurisdiction, Hon'ble High Court Division of the Supreme Court of Bangladesh.(cont4)
2019-12-15: Cont2-Auditor's Opinion
SQURPHARMA(cont2):and Square Pharmaceuticals Ltd. is to reform Square Pharmaceuticals Ltd; into a diversified high performance and value added company, Board of Directors considered a proposal for amalgamation of Square Herbal and Nutraceuticals Ltd. with Square Pharmaceuticals Ltd. under provision of section 228 and 229 of the Companies Act 1994. The Process of Merger: After approval of Board of Directors and consent of minority shareholders, the Hon'ble High Court Division of the Supreme Court of Bangladesh has sanctioned the scheme of amalgamation of Square Formulations Ltd. with Square Pharmaceuticals Ltd. on 29th October, 2018. (cont3)
2019-12-15: Cont1-Auditor's Opinion
SQURPHARMA(cont1): Our opinion is not modified in respect of this matter. The financial statements reflects financial result of the amalgamated entity. Note 1.28 Merger with Square Formulations Ltd. and Square Herbal and Nutraceuticals Ltd.: As the project of Square Formulations Ltd. (SFRL) is located within the premises of Square Pharmaceuticals Ltd. (SPL) at Kaliakoir, the separated operations of various aspects of SFRL is a complex one. Since SPL holds 99.50% of the Paid-up Capital of SFRL with only 0.50% being held by the minority shareholders, Board of Directors have recommended for amalgamation under provision of section 228 and 229 of the Companies Act 1994. Reason of merger between Square Herbal and Nutraceuticals Ltd.(cont2)
2019-12-15: Auditor's Opinion
SQURPHARMA: The auditor of Square Pharmaceuticals Ltd. has given the following emphasis of Matter in the audit report of the Company for the year ended on 30 June 2019: ''Emphasis of Matter: We draw attention to Note 1.28 to the financial statements which describe the amalgamation of the fully owned subsidiary the Square Formulations Ltd. and the Square Herbal and Nutraceuticals Ltd. with the Company. The Board of Directors of the Company in its meeting held on 16th October 2017 approved the amalgamation of the Company with the Subsidiary and with the Square Herbal and Nutraceuticals Ltd. whereby the Subsidiary and Square Herbal and Nutraceuticals Ltd. will merge with the Company, and the Company shall be the surviving entity.(cont1)
2019-11-20: Ex-benefit Price Adjustments
SQURPHARMA: Please note that the price of the shares of SQURPHARMA is adjusted today following its ex-benefits date to the extent of its corporate benefits; hence the price limit on the scrip will remain as it is today. Therefore, adjusted price of SQURPHARMA =Tk 222.90.
2019-11-18: Record Date tomorrow (19.11.2019)
SQURPHARMA: Trading of the shares of Square Pharmaceuticals Ltd. will remain suspended on its record date i.e., 19.11.2019. Trading of the shares of the Company will resume on 20.11.2019.
2019-11-14: Spot trade from 17.11.2019
SQURPHARMA: Trading of the shares of Square Pharmaceuticals Ltd. will be allowed only in the Spot Market from 17.11.2019 to 18.11.2019 as the record date of the Company is on 19.11.2019.
2019-11-14: Un-audited Financial Statements
SQURPHARMA: (Quarter 1) As per un-audited financial statements of Square Pharmaceuticals Ltd., Consolidated EPS was Tk. 4.25 for July-September 2019 as against Tk. 4.02 for July-September 2018; Consolidated NOCFPS was Tk. 4.14 for July-September 2019 as against Tk. 4.06 for July-September 2018. Consolidated NAV per share was Tk. 90.00 as on September 30, 2019 and Tk. 86.03 as on June 30, 2019.
2019-11-07: Board Meeting
SQURPHARMA: Square Pharmaceuticals Ltd. has informed that the Board Meeting of the Company will be held on November 13, 2019 at 3:00 PM to consider, among others, un-audited financial statements of the Company for the First Quarter (Q1) period ended on September 30, 2019.
2019-10-23: CB free
SQURPHARMA: Please note that there will be no price limit today 23 October 2019 on the trading of shares of the Company following its corporate disclosure.
2019-10-23: Cont-Recommendation of Dividend and BMRE, Capital Machineries & Land purchase
SQURPHARMA(cont):The Company also informed that a) Bonus shares has been recommended in view to utilize its retained amount as capital for business expansion. b) Bonus share is declared out of accumulated profit. c) Bonus share is not declared from capital reserve or revaluation reserve or any unrealized gain or out of profit earned prior to incorporation of the Company or through reducing paid up capital or through doing anything so that the post dividend retained earnings become negative or a debit balance.(end)
2019-10-23: Recommendation of Dividend and BMRE, Capital Machineries & Land purchase
SQURPHARMA: The Board of Directors has recommended 42% cash and 7% stock dividend for the year ended on June 30, 2019. The Board has also approved Tk. 200.00 crore for BMRE, Capital Machineries and Lands for future expansion. Date of AGM: 12.12.2019, Time: 10:00 AM, Venue: Samson H Chowdhury Centre Dhaka Club Ltd., Ramna, Dhaka. Record Date: 19.11.2019. The Company has also reported Consolidated EPS of Tk. 16.03, Consolidated NAV per share of Tk. 86.03 and Consolidated NOCFPS of Tk. 15.71 for the year ended on June 30, 2019 as against Tk. 14.69, Tk. 73.28 and Tk. 12.55 respectively for the same period of the previous year.(cont)
2019-10-10: Board Meeting
SQURPHARMA: Square Pharmaceuticals Ltd. has informed that the Board Meeting of the Company will be held on October 22, 2019 at 3:00 PM to consider, among others, audited financial statements of the Company for the year ended on June 30, 2019.
2019-01-31: Un-audited HY A/Cs
SQURPHARMA: (Quarter 2) As per un-audited half yearly accounts of Square Pharmaceuticals Ltd., Consolidated EPS was Tk. 3.96 for October-December, 2018 as against Tk. 3.62 for October-December, 2017; Consolidated EPS was Tk. 7.98 for July-December, 2018 as against Tk. 7.43 for July-December, 2017. Consolidated NOCFPS was Tk. 7.32 for July-December, 2018 as against Tk. 8.09 for July-December, 2017. Consolidated NAV per share was Tk. 77.90 as on December 31, 2018 and Tk. 73.28 as on June 30, 2018.
2019-01-28: Cash Dividend Disbursement
SQURPHARMA: Square Pharmaceuticals Ltd. has informed that the Cash Dividend for the year ended on June 30, 2018 has been disbursed.
2019-01-24: Board Meeting
SQURPHARMA: Square Pharmaceuticals Ltd. has informed that the Board Meeting of the Company will be held on January 30, 2019 at 3:00 PM to consider, among others, un-audited financial statements of the Company for the Second Quarter (Q2) period ended on December 31, 2018.
2019-01-03: Bonus Share Credited
SQURPHARMA: Square Pharmaceuticals Ltd. has informed that the Bonus Shares of the Company for the year ended on June 30, 2018 have already been credited through CDBL to the respective shareholders' BO Accounts on January 02, 2019.
2018-12-27: Credit Rating
SQURPHARMA: Credit Rating Information and Services Limited (CRISL) has informed that the Rating Committee of CRISL has assigned the rating to Square Pharmaceuticals Ltd. as "AAA" in the long term and "ST-1" in the short term along with a stable outlook in consideration of its audited financials up to June 30, 2018; un-audited financials up to September 30, 2018 and other relevant quantitative as well as qualitative information up to the date of rating declaration.
2018-11-28: Ex-benefit Price Adjustments
SQURPHARMA: Please note that the price of the shares of SQURPHARMA is adjusted today following its ex-benefits date to the extent of its corporate benefits; hence the price limit on the scrip will remain as it is today. Therefore, adjusted price of SQURPHARMA =Tk 257.00.
2018-11-26: Record Date tomorrow (26.11.2018)
SQURPHARMA: Trading of the shares of Square Pharmaceuticals Ltd. will remain suspended on its record date i.e., 27.11.2018. Trading of the shares of the Company will resume on 28.11.2018.
2018-11-22: Spot trade from 25.11.2018
SQURPHARMA: Trading of the shares of Square Pharmaceuticals Ltd. will be allowed only in the Spot Market from 25.11.2018 to 26.11.2018 as the record date of the Company is on 27.11.2018.
2018-11-14: Un-audited Financial Statements
SQURPHARMA: (Quarter 1) As per un-audited financial statements of Square Pharmaceuticals Ltd., Consolidated EPS was Tk. 4.30 for July-September, 2018 as against Tk. 4.08 for July-September, 2017; Consolidated NOCFPS was Tk. 4.34 for July-September, 2018 as against Tk. 5.04 for July-September, 2017. Consolidated NAV per share was Tk. 82.82 as on September 30, 2018 and Tk. 78.41 as on June 30, 2018.
2018-11-07: Board Meeting
SQURPHARMA: Square Pharmaceuticals Ltd. has informed that the Board Meeting of the Company will be held on November 13, 2018 at 3:00 PM to consider, among others, un-audited financial statements of the Company for the First Quarter (Q1) period ended on September 30, 2018
2018-10-22: CB free
SQURPHARMA: Please note that there will be no price limit today 22 October 2018 on the trading of shares of Square Pharmaceuticals Ltd. following its corporate disclosure.
2018-10-22: Financial Information
SQURPHARMA: Square Pharmaceuticals Ltd. also reported consolidated EPS of Tk. 15.72, Consolidated NAV per share of Tk. 78.41 and Consolidated NOCFPS of Tk. 13.57 for the year ended on June 30, 2018 as against Tk. 14.43, Tk.66.49 and Tk. 12.94 respectively for the same period of the previous year.
2018-10-22: Recommendation of Dividend
SQURPHARMA: Square Pharmaceuticals Ltd. has recommended 36% cash and 7% stock dividend for the year ended on June 30, 2018. The Board has also approved Tk. 200.00 crore for BMRE, Capital Machinery and Lands for future expansion. AGM will be held on 20 December at 10:00 AM, at Samson H Chowdhury Centre Dhaka Club Ltd., Ramna, Dhaka. Record Date is on 27 November, 2018.
2018-10-08: Board Meeting
SQURPHARMA: Square Pharmaceuticals Ltd. has informed that the Board Meeting of the Company will be held on October 21, 2018 at 3:00 PM to consider, among others, audited financial statements of the Company for the year ended on June 30, 2018.
CSE News
©2024 Chittagong Stock Exchange PLC. All rights reserved.